Answers are grounded in this paper and cite their sources.
Randomized controlled trials (RCTs) of a new investigational drug often include active as well as placebo control arms. The active arm, comprising an approved treatment for the indication under study, along with the placebo arm, are together required to establish assay sensitivity; if the active treatment outperforms placebo, as expected, the results of the RCT can be further interpreted, but if the active treatment is no better than placebo (such as because of ceiling or floor effects), the RCT is a failed trial. The concepts involved are explained from scientific and ethical perspectives.
No takes yet. Share an insight, caveat, or question.
Chittaranjan Andrade (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: